



Join Zoom Meeting

<https://rutgers.zoom.us/j/96718538458?pwd=0SLcApXvYJ9LM2HKznRheuuamWrbEL.1>


Join In-Person Meeting - MEB Lecture Hall Room 102

Surgical Grand Rounds

Provided by Rutgers Robert Wood Johnson Medical School, Department of Surgery

**Wednesday,
MEB-102**

March 18, 2026 - 8:00 – 9:00am



Ding Ding, MD
General Surgery Chief Resident
Rutgers Health Robert Wood Johnson Medical School

“Lung Cancer Screening”

Learning Objectives

At the conclusion of this activity, participants should be better able to:

- History of lung cancer screening
- Current issues
- Possible Future strategies

Target Audience

This activity is designed for surgeons, anesthesiologists, researchers, residents, fellows, physician assistants, nurse practitioners, registered nurses, medical students, and other healthcare providers interested in this topic.

Accreditation



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1- *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Declarations

Ding Ding, MD has no relevant financial relationships with ineligible companies to disclose. Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee: Activity Directors: Susannah Wise, MD and Content Reviewer: Kristen Donohue, MD have no relevant financial relationships with ineligible companies to disclose.

Rutgers Health CE Staff: Patrick Dwyer and Elizabeth Ward have no relevant financial relationships with ineligible companies to disclose.